08/09/2026
💊 An Arthritis Drug Helped People With Severe Alopecia Regrow Significant Amounts of Hair
A medication commonly used to treat inflammatory diseases has shown promising results for people with severe alopecia areata, an autoimmune condition in which the immune system attacks hair follicles.
Two Phase 3 clinical trials involving 1,399 participants found that upadacitinib (Rinvoq) produced substantial scalp-hair regrowth within 24 weeks. All participants began the studies with at least half of their scalp hair missing.
Among those receiving the higher dose:
🔹 54–55% achieved at least 80% scalp-hair coverage, compared with about 2–3% receiving placebo.
🔹 Approximately 20–23% achieved complete scalp-hair coverage.
🔹 Differences in hair coverage were already evident by week 8.
🔹 Participants also reported improvements in quality of life.
Upadacitinib works by blocking JAK1, an enzyme involved in immune signaling. By reducing certain immune signals, the drug may help interrupt the attack on hair follicles and allow hair growth to resume.
The trials included 118 adolescents, with participants taking either 15 mg or 30 mg of upadacitinib daily or a placebo.
⚠️ But there is an important distinction: These findings apply to alopecia areata, not ordinary male- or female-pattern hair loss. The results also do not mean the drug is a permanent cure.
Safety remains an important consideration. Serious adverse events occurred in 1.6–2.3% of treated participants compared with 0.4% in the placebo group, although these events were not necessarily caused by the treatment. Upadacitinib also carries established warnings, including risks of serious infections and blood clots.
The drug’s manufacturer, AbbVie, funded and helped design the trials. The published analysis covers the first 24 weeks, with longer-term follow-up continuing.
📌 Bottom line: The findings are encouraging for people living with severe alopecia areata, but they show hair regrowth during treatment, not proof of a permanent cure or that upadacitinib is superior to every existing alopecia treatment.
📖 SOURCE:
Upadacitinib for Severe Alopecia Areata in Adults and Adolescents. JAMA Dermatology.